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Abstract 
It is not yet known, if critically ill COVID-19 patients are prone to fungal infections. We report a 69-
year-old patient without typical risk factors for invasive pulmonary aspergillosis (IPA), who developed 
IPA two weeks after onset of symptoms. Our report shows that IPA may occur in critically ill COVID-
19 patients. 
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Introduction 
 
Aspergillus is an opportunistic fungal pathogen that may cause devastating disease in 
immunocompromised hosts, including those with hematological malignancies. Aspergillus is an air-
borne pathogen, bringing the lungs in the frontline for defense. Recently, severe viral pulmonary 
infections have shown to be associated with an increased risk for invasive pulmonary aspergillosis 
(IPA). Severe influenza in critically ill patients for example, is complicated by IPA in 7-23% of cases 
and associated with a case fatality rate of more than 50% (1). Similar to influenza, the newly emerged 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may cause severe lower respiratory 
tract infections leading to acute respiratory distress syndrome (ARDS). The proportion of patients 
with coronavirus disease 2019 (COVID-19) who develop severe disease with ARDS is considerably 
high (2). Consequently, there is a large number of patients in need for intensive care unit (ICU) 
admission. It is not yet known, if patients with severe COVID-19 are at similar risk for IPA 
development as patients with severe influenza.   
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Case 
 
Here we report a 70-year-old male who was diagnosed with COVID-19 in March 2020. Underlying 
diseases included chronic obstructive pulmonary disease (COPD) GOLD grade 2, obstructive sleep 
apnea syndrome, insulin-dependent type 2 diabetes with end-organ damage [retinopathy, 
nephropathy (CKD 3b according to the KDIGO classification at first presentation), polyneuropathy], 
arterial hypertension, coronary heart disease and obesity (body mass index: 38 kg/m
2
). Past medical 
history included proximal deep vein thrombosis four months prior to presentation. His medication 
consisted of a long-acting beta agonist/long-acting muscarinic antagonist combination, inhaled 
glucocorticoid (400 µg budesonide per day), valsartan, spironolactone, ivabradine, atorvastatin, 
metformin, liraglutide, insulin glargine and enoxaparin.  
The patient presented with productive cough, dyspnea and intermittent fever (>38.5°C) for one week 
(figure 1). Arterial pO2 was 67mmHg while breathing ambient air. White blood cell count was within 
the normal limits and C-reactive protein (CRP) was slightly elevated (33 mg/dl; upper limit of norm 5 
mg/dl). D-dimer was within the normal range. Chest X-ray revealed bilateral basal coarse reticular 
opacities (figure 2a and 2b). Real-time polymerase chain reaction (PCR) from oropharyngeal swab 
was positive for SARS-CoV-2. However, the patient refused to be hospitalized due to personal 
reasons and was discharged home with oral doxycycline 200 mg q.d. One week later, the patient 
returned to the emergency department because of clinical deterioration and hypoxemia (arterial pO2 
46 mmHg while breathing ambient air). Chest CT-scan was performed and showed multiple bilateral 
ground-glass opacities with a crazy paving appearance (figure 2c). In addition, a reversed halo sign 
was described (figure 2d). White blood-cell count was slightly elevated (11.65 x 10^
9
 per L), 
neutrophils were elevated (9.7 x 10^
9
 per L), CRP level was 144 mg/dl, interleukin-6 was 396 pg/ml 
and ferritin 465 ng/ml. Creatinine levels increased from 1.85 mg/dl (first presentation) to 3.26 mg/dl. 
Lymphocytes were within the normal range. The patient was admitted to ICU with moderate ARDS 
(oxygenation index 154) and received meropenem 1 g b.i.d., azithromycin 500mg once q.d., and 
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hydroxychloroquine 200mg b.i.d. He was intubated and mechanically ventilated. Chest X-ray 
revealed a progression of the bilateral infiltrates on day 2 after ICU admission concordant with 
significant pulmonary deterioration (oxygenation index <100). On day 3 of ICU stay (day 14 after 
onset of symptoms) endotracheal aspiration was obtained. Culture grew Aspergillus fumigatus 
(voriconazole minimal inhibitory concentration 0.125 mg/L), without bacterial growth.  Aspergillus 
lateral-flow device (LFD) (3), detecting an Aspergillus specific antigen secreted during active growth 
of Aspergillus and not during colonization, was performed from the endotracheal aspirate and 
revealed a positive result. Due to low sample volume, galactomannan could not be performed from 
this respiratory specimen. Serum fungal biomarkers (galactomannan and 1,3-ß-D-glucan) remained 
negative. Based on progression of pulmonary infiltrates, recovery of Aspergillus fumigatus in 
endotracheal aspirate, positive LFD in endotracheal aspirate and the clinical deterioration the patient 
was diagnosed with putative invasive pulmonary aspergillosis according to Blot et al. (4)  and 
intravenous voriconazole (6 mg/kg b.i.d followed by 4 mg/kg b.i.d.) was initiated on day 4 of ICU stay. 
Despite treatment of ICU and addition of voriconazole, the patient deceases 3 days after initiation of 
antifungal treatment due to multiorgan failure. Autopsy was not performed.  
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Discussion 
  
From early reports from Wuhan, we know that patients with COVID-19 may develop complicating 
fungal infections (5). However, galactomannan testing and other fungal diagnostics for further 
differentiating these infections are rarely available in the Wuhan region and China in general (6). 
Here we report a case of putative invasive aspergillosis in a patient with COVID-19 associated ARDS, 
with growth of Aspergillus fumigatus and a positive Aspergillus-Ag test in endotracheal aspirate. The 
patient presented in this report had a two-week history of symptoms before he was admitted to the 
ICU. On ICU admission, a CT scan revealed a reversed halo sign that is usually suspicious for the 
presence of mucormycosis (7)  but may also be found in other mold infections, particularly IPA (8). 
Chest CT scans are a valuable tool for COVID-19 diagnosis and management. Ground-glass opacities 
with or without consolidations are observed in the majority of COVID-19 cases (9, 10) but a reversed 
halo may be observed in some patients (9). Similar to patients with severe influenza a halo or 
reversed halo sign may be indicative for presence of a pulmonary mold infection (11) and should 
therefore trigger further diagnostic steps to confirm or rule out IPA. 
For further diagnostic workup, endotracheal aspiration was performed and yielded growth of 
Aspergillus fumigatus. To further discriminate between colonization and infection we tested the 
Aspergillus specific LFD, a CE-certified point of care assay, specific for Aspergillus. This test detects 
actively growing hyphae during invasive infection and remains negative in case of Aspergillus 
colonization of the airways. The LFD was recently given an BII recommendation for diagnosis of 
invasive aspergillosis in the ESCMID/ECMM/ERS guidelines (12).  
While serum galactomannan generally lacks sensitivity in non-neutropenic patients (13), and also 
turned out negative in this patient, further studies are needed to evaluate the benefit of serum GM 
screening in COVID-19 patients where bronchoalveolar lavage fluid sampling for culture and 
biomarker testing is often avoided due to the risk of aerosol spreading and health care worker 
infections. This seems to be of special interest as based on the data from a recently published trial, 
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showing that GM in serum is indeed elevated in the majority of patients with severe influenza (14) on 
ICU and the fact that a significant amount of IPA cases on ICU are still diagnosed post-mortem only, 
serum GM screening may be an important tool for early recognition of IPA in critically ill COVID-19 
patients. 
Diagnosis of IPA in ICU patients without classical risk factors for IPA remains challenging. The well-
established criteria of the European Organization for Research and Treatment of Cancer/Mycoses 
Study Group (EORTC/MSG) (14) are not applicable for many of the ICU patients due to a missing host 
factor. Thus, new diagnostic criteria for ICU patients were established to overcome these limitations 
(4). This criteria base on clinical signs and symptoms compatible with IPA, abnormal chest imaging of 
the lungs and microbiological evidence of presence of Aspergillus. This criteria turned out to be 
superior to the EORCT/MSG criteria in the ICU setting (4). Also the patient reported in this case 
report would not have been classified as IPA according to the EORTC/MSG criteria from 2008 due to 
a missing host factor. Recently, in the influenza and aspergillosis trial, GM in serum and 
bronchoalveolar lavage fluid was added to the ICU criteria as an additional mycological criterium to 
overcome the limitation of imperfect culture sensitivity for aspergillosis (15).  
The patient reported here had no classical risk factors for IPA, but it is well known, that viral 
infections like influenza or cytomegalovirus infections increase the risk for IPA. The pathogenetic 
mechanisms rendering patients susceptible for IPA during such viral infections are not completely 
understood at the moment but probable include viral induced overexpression of anti-inflammatory 
cytokines, dysregulation of T-helper cell differentiation and impaired cell-mediated immune 
response (16, 17). It is likely, that during SARS-CoV-2 infections similar impairment are present 
putting the patients at risk for complicating mold infections as seen in our patient. 
Our case report highlights that IPA may occur in in critically ill COVID-19 patients. Screening studies 
are needed to evaluate the prevalence of IPA in COVID-19 patients admitted to ICU.  
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Figure 1 Timeline representing the course of COVID-19 in the reported patient 
 
 
 
Abbreviations: q.d. = once daily; b.i.d. = twice daily, i.v. = intravenous; LFD = lateral-flow device; ER = emergency room; ARDS = acute respiratory 
distress syndrome; ICU = intensive care unit; SARS-CoV-2 = Severe acute respiratory syndrome coronavirus 2, CT = computed tomography 
* Voriconazole dosage: 6 mg/kg twice daily on day 1, followed by 4 mg/kg twice daily 
Chest imagings displayed here are also displayed in more detail in Figure 2.  
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Figure 2 Figure 2a and 2b representing findings on chest X-ray performed on day 6 of symptom onset. The lateral chest view revealed bilateral 
dorsal and basal coarse reticular opacities, no pleural effusions. Figure 2c and 2d representing chest CT scans on day 12 of symptom onset. Axial 
CT image of the chest demonstrate extensive-ground glass opacities with bilateral and multi-lobar distribution (2c) and a combination of 
consolidation and surrounding ground-glass opacities basal in the posterior left lower lung (“reversed halo sign” - shown by the arrow) (2d) 
 
 
Highlights: 
1.) Invasive pulmonary aspergillosis may complicate severe Covid-19 
2.) Physicians should be aware for aspergillosis in critically ill Covid-19 patients 
3.) Screening for aspergillosis may be indicated in these patients 
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